Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

YANG-CHENG LEE; WEN-TSUNG HUANG; MING-YANG LEE; CHAO-JUNG TSAO; YIN-HSUN FENG

doi:10.21873/invivo.13099

Article Information

vol. 37 no. 1 454-460

DOI

https://doi.org/10.21873/invivo.13099

PubMed

36593061

Published By

International Institute of Anticancer Research

Print ISSN

0258-851X

Online ISSN

1791-7549

History

Received October 4, 2022
Revision received October 20, 2022
Accepted October 24, 2022
Published online January 2, 2023.

Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

YANG-CHENG LEE¹,²,#,
WEN-TSUNG HUANG³,#,
MING-YANG LEE⁴,
CHAO-JUNG TSAO³ ⇑ and
YIN-HSUN FENG⁵ ⇑

¹Division of Hematology and Oncology, Department of Internal Medicine, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan, Taiwan, R.O.C.;
²Chung Hwa University of Medical Technology, Tainan, Taiwan, R.O.C.;
³Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan, R.O.C.;
⁴Department of Internal Medicine, Chia-Yi Christian Hospital, Chia-Yi, Taiwan, R.O.C.;
⁵Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan, R.O.C.

Correspondence to: Yin-Hsun Feng, MD, Ph.D., Department of International Medicine, Chi Mei Medical Center, No. 901, Zhonghua Rd., Yongkang District, Tainan City 71004, Taiwan, R.O.C. E-mail: yinhsun.feng{at}gmail.com
Correspondence to: Chao-Jung Tsao, MD, Ph.D., Department of Hematology and Oncology, Chi Mei Medical Center, No. 201, Taikang, Liouying District, Tainan City 73657, Taiwan, R.O.C. E-mail: cjt{at}mail.chimei.org.tw